NCT00724906 (POET-2) is a Phase 3 clinical trial of 123 I - ALTROPANE® in Parkinsonian Syndromes, sponsored by Alseres Pharmaceuticals, Inc.

Who is sponsoring NCT00724906?

NCT00724906 is sponsored by Alseres Pharmaceuticals, Inc.

What drugs are being tested in NCT00724906?

Interventions in NCT00724906: 123 I - ALTROPANE®.

What condition does NCT00724906 study?

NCT00724906 studies Parkinsonian Syndromes.

Is NCT00724906 still recruiting?

NCT00724906 is currently status unknown. Last updated 2 February 2010.

Last reviewed 2010-02-02 · How we verify

NCT00724906: POET-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Diagnostic Accuracy and Safety of 123 I-ALTROPANE® as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes (POET-2)

Status unknown Phase 3 Last updated 2 February 2010

What this trial tests

Phase 3 trial testing 123 I - ALTROPANE® in Parkinsonian Syndromes in 240 participants. Status unknown.

Timeline

1 July 2010

Primary endpoint
1 July 2011

1 July 2011

Quick facts

Lead sponsor	Alseres Pharmaceuticals, Inc
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	240
Start date	1 July 2010
Primary completion	1 July 2011
Estimated completion	1 July 2011
Sites	1 location across United States

Drugs / interventions tested

123 I - ALTROPANE® — full drug profile →

Conditions studied

Parkinsonian Syndromes — all drugs for Parkinsonian Syndromes →

Sponsor

Alseres Pharmaceuticals, Inc — full company profile →

Who can join

Adults 40 to 80, any sex, with Parkinsonian Syndromes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To evaluate the diagnostic accuracy of a single dose of 123 I-ALTROPANE® as an imaging agent to aid in the diagnosis of Parkinsonian syndromes (PS) in subjects with upper extremity tremor for less than 2 years.
Time frame: 7 months

Sponsor's own description

This will be two separate but identical studies: ALSE-A-02a, ALSE-A02b. Each study is designed to evaluate the diagnostic accuracy and safety of a single dose of 123I-ALTROPANE® in subjects with upper extremity tremor for less than three years. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S. for use in diagnosing Parkinson disease and related Parkinsonian syndromes. The diagnosis of Parkinsonian syndromes in the U.S. is based on clinical criteria only. The goal is to demonstrate that 123I-ALTROPANE® paired with SPECT imaging permits a more accurate early diagnosis of Parkinson disease than a clinical diagnosis by a general neurologist.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00724906 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alseres Pharmaceuticals, Inc
Last refreshed: 2 February 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00724906.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing